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Abstract
Background: A common feature of diagnostic research is that results for a diagnostic gold
standard are available primarily for patients who are positive for the test under investigation. Data
from such studies are subject to what has been termed "verification bias". We evaluated statistical
methods for verification bias correction when there are few false negatives.
Methods: A simulation study was conducted of a screening study subject to verification bias. We
compared estimates of the area-under-the-curve (AUC) corrected for verification bias varying
both the rate and mechanism of verification.
Results: In a single simulated data set, varying false negatives from 0 to 4 led to verification bias
corrected AUCs ranging from 0.550 to 0.852. Excess variation associated with low numbers of false
negatives was confirmed in simulation studies and by analyses of published studies that
incorporated verification bias correction. The 2.5th – 97.5th centile range constituted as much as
60% of the possible range of AUCs for some simulations.
Conclusion: Screening programs are designed such that there are few false negatives. Standard
statistical methods for verification bias correction are inadequate in this circumstance.
Background
A common feature of diagnostic research is that results for
a diagnostic gold standard are available only for patients
who are positive for the test under investigation. Prostate-
specific antigen (PSA) testing is a typical example: we
want to know the operating characteristics of the PSA test,
but men are only recommended for biopsy (the gold
standard assessment of prostate cancer) if their PSA is
above a specified threshold, such as 4 ng/ml. Accordingly
we have little information on whether men with PSA less
than 4 mg/ml do or do not have prostate cancer. True dis-
ease state is therefore known for only a subset of partici-
pants, and because that subset is determined by the
diagnostic test result, data are subject to what has been
termed "verification bias"[1]. Verification bias is associ-
ated particularly with screening tests: screening a healthy
population for a symptomless disease will, by definition,
result in further diagnostic work up only for those with a
positive screening test.
Begg and Greenes have proposed straightforward Baye-
sian methods to correct for verification bias [1,2]. Their
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ple computations to estimate sensitivity and specificity for
each threshold of the diagnostic test result, which can
then be used to derive the area-under-the-receiver-operat-
ing-characteristics-curve (AUC). Alonzo and Pepe recently
described another method for computing the AUC of a
continuous screening test in the presence of verification
bias. This method involves computing the sensitivity and
specificity for each observed value of the screening test,
but again is straightforward to implement[10]. Both of
these methods rely on the assumption that data are miss-
ing at random[11], in other words, no other factor besides
the diagnostic test result influenced verification status.
Hunink et al have reported a method of correcting for ver-
ification bias when some participants receive the gold
standard test based on variables other than the diagnostic
test result, for example, if patients were sent to biopsy as a
result of clinical findings. This method is similar to the
method proposed by Begg and Greenes, but includes an
additional modeling step [12].
One characteristic of many studies subject to verification
bias, particularly those based on screening studies, is that
only a very small number of participants with normal
diagnostic test results will subsequently receive the gold
standard assessment, that is, the number of false negatives
is very low. It has previously been demonstrated that sen-
sitivity cannot be accurately estimated in this scenario,
even after correction for verification bias[13]. Here, we
extend this argument to the area-under-the-receiver-oper-
ating-characteristic-curve. We also describe several previ-
ously published studies that involved verification bias
correction, and examine whether their results might have
been influenced by low false negative counts.
Methods
Take the case of study of screening for cancer, where the
aim is to determine the relationship between results of the
screening test and true disease status. Patients are screened
using an imaging technology (the diagnostic test), and
those with abnormal findings recommended for biopsy
(the gold standard assessment). A hypothetical example
from such a screening program is shown in Figure 1. A
total of 500 patients are screened and 100 have abnormal
findings. Since those with abnormal findings are strongly
recommended to undergo biopsy, 75/100 decide to have
a biopsy and 50/75 are confirmed to have disease present.
Of the 400 patients with normal findings, 40 are nonethe-
less biopsied, and 5 are found to have disease.
To estimate the sensitivity and specificity of imaging for
detecting cancer, the naive approach would be to use only
data from biopsied patients. This results in a sensitivity of
91% (50/55) and a specificity of 58% (35/60). However,
it is obvious that patients with unfavorable characteristics
(those likely to be both diagnostic and gold standard pos-
itive) are overrepresented and patients with favorable
characteristics (those likely to be both diagnostic and gold
standard negative) are underrepresented in the sample of
biopsied patients. As a result, sensitivity is overestimated
and specificity underestimated. This is a classic example of
verification bias: imaging results are available for all 500
patients, but the gold standard available only for a subset,
which is associated with the imaging result. Methods for
verification bias correction, following Begg and Greenes
[1] are given in the Appendix (see Additional file 1). Using
these methods on our example data set, gives a corrected
sensitivity of 57% (67/117) and specificity is 91% (350/
383). Without verification bias correction, we would have
concluded that imaging was highly sensitive but moder-
ately specific when in fact the reverse is true.
Correction for verification bias becomes problematic if
small cell counts are encountered. Table 1 gives some dif-
ferent scenarios for the biopsy results of patients with a
normal imaging result in our cancer screening example. In
the first row, the scenario shown in figure 1, 40 partici-
pants with a normal imaging result were biopsied, of
which 5 were found with disease – that is, there were 5
false negatives – giving a corrected sensitivity of 57%. In
subsequent rows in table 1, we vary the number of false
negatives and find that small changes in the data lead to
large differences in our estimates: a change from 2 to 1
false negatives, for example, increases sensitivity from
77% to 87%. Clearly no robust statistical method should
give such a different result given a change in status for a
single patient in a 500 patient study.
A mathematical explanation for this observation is as fol-
lows. Consider the formula for the corrected sensitivity
given in the appendix (see Additional file 1):
Here, v indicates patients with verified outcome (e.g. a
biopsy result); n indicates all patients; the first and second
subscripts refer to the test and gold standard results (e.g.
imaging and biopsy) respectively; the subscript indicator
1 and 2 refer to test positive/disease and test negative/no
disease. The problematic cell is the false negative cell,
since participants are rarely verified if they have a strongly
negative diagnostic test result; moreover, when these
patients are verified, they are most likely to be disease free.
It can be seen from (1) that as the false negative cell count
(v21) approaches zero, the second term in the denomina-
tor of (1) also approaches zero, resulting in a corrected
sensitivity that approaches 100%.
Corrected sensitivity
v v v n
v v v n
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have shown, can have a marked effect on estimates, are an
inevitable consequence of sampling variability. In our
principal example, 5 of the 40 patients with negative
imaging results had positive biopsy. The 95% confidence
interval for this proportion, 12.5%, is 4% to 27%: accord-
ingly it would not at all be unusual if, were we to repeat
this experiment, we were to see only 2 of 40 patients with
false negative results. In other words, in the imaging
example we could have reported a sensitivity ranging from
Example of data subject to verification biasFigure 1
Example of data subject to verification bias.
Table 1: Examples of data subject to verification bias and with a low number of false negatives
Example Number with normal imaging result and biopsied Corrected Sensitivity* (%)
Diseased (False negatives) Nondiseased (True negatives) Total
1 5 35 40 57
2 4 36 40 63
3 3 37 40 69
4 2 38 40 77
5 1 39 40 87
6 0 40 40 100
* Corrected for verification biasPage 3 of 9
(page number not for citation purposes)
BMC Medical Research Methodology 2008, 8:75 http://www.biomedcentral.com/1471-2288/8/75approximately 40% to 75% due to small chance differ-
ences in the number of false negatives, and there would be
a very wide confidence interval around these estimates.
To investigate further the effects of low false negative
counts on sensitivity, and in turn the AUC, we performed
the following experiment:
A) We created a simulated data set with 5000 subjects.
Both diagnostic and gold standard test results were known
for all 5000 subjects, constituting a fully verified data set.
Since the gold standard result was known for all subjects,
we were able to fix the true AUC to 0.750. Data were sim-
ulated according to the specified probability models:
a. The gold standard test result follows a Bernoulli distri-
bution with the mean equal to the incidence of disease,
which was set to 10%.
b. The diagnostic test result follows a log normal distribu-
tion where the log(test result) has a standard deviation of
1 and a mean of 0 and 1, respectively, for patients with
negative and positive gold standard test results.
B) We introduced verification bias to the data in step A
such that a certain proportion v of participants were veri-
fied, where v was varied as an experimental parameter.
The probability p of verification for each subject increased
with the diagnostic test result using the formula log [p/(1-
p)] = α + 0.5d, where d was the decile of the diagnostic test
result and the constant α adjusted to fix the overall prob-
ability of verification to v. This gives the probabilities
shown in the top half of table 2. We then applied a correc-
tion for verification bias, as shown in the appendix. Note
that verification status depended solely on the diagnostic
test result, therefore fulfilling the missing at random
assumption required for this method. Since the diagnostic
test in our simulation has a continuous distribution, the
sensitivity and specificity was derived for multiple thresh-
olds by dichotomizing the subjects into abnormal (above
the threshold) and normal (below the threshold). A
receiver operating characteristics curve was then con-
structed from these estimates [2] to calculate an AUC cor-
rected for verification bias.
C) We repeated step B five times. Since we introduced ver-
ification bias in the same manner each time, we would
expect no important differences in data structure between
replications. Using the same argument, we would expect
no important difference in verification bias corrected AUC
unless standard methods were not appropriate for these
data.
Table 2: Probability of verification used in the simulations for each decile of the diagnostic test result
Decile of diagnostic test result Probability of having the gold standard result (%)
10% verified 30% verified 60% verified
Probabilities of verification likely to be encountered in a screening study
1 0.6% 3.0% 16.0%
2 0.9% 4.9% 23.9%
3 1.5% 7.8% 34.2%
4 2.5% 12.2% 46.1%
5 4.1% 18.7% 58.5%
6 6.5% 27.5% 69.9%
7 10.3% 38.5% 79.3%
8 15.9% 50.7% 86.3%
9 23.8% 62.9% 91.2%
10 34.0% 73.7% 94.5%
Probabilities of verification were adjusted such that false negatives were more (less) likely to be present for 10% (60%) verified
1 6.4% -- 0.0%
2 7.0% -- 0.0%
3 7.7% -- 0.1%
4 8.5% -- 7.6%
5 9.3% -- 92.4%
6 10.2% -- 99.9%
7 11.1% -- 100.0%
8 12.1% -- 100.0%
9 13.2% -- 100.0%
10 14.4% -- 100.0%Page 4 of 9
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tion bias corrected AUC corresponding to each replication
from step C.
The AUC was calculated using the trapezoid rule, where
sensitivity and specificity were estimated (a) over 10 cate-
gories based on the deciles of the diagnostic test result and
(b) for each unique value of the diagnostic test result
using semiparametric efficient estimators – subsequently
referred to as the Alonzo-Pepe method -, the latter of
which has been shown to have minimal bias when the
verification mechanism is known[10]. We specified that
the simulated set have 5000 participants with 10% verifi-
cation since these are common characteristics of large
screening studies [4,7,9].
We performed a simulation experiment where we
repeated steps A and B 2000 times and report the mean of
the true and verification bias corrected AUC, as well as the
2.5th – 97.5th percentiles and coverage. Coverage was the
proportion of 95% confidence intervals, constructed
using bootstrap methods with 2000 replications, contain-
ing the true value of 0.750. We performed this simulation
experiment varying the proportion verified (v = 10, 30,
and 60%). Our intent in varying the proportion verified
was to vary the frequency of the cell counts while keeping
the relationship between the diagnostic test and outcome
the same. For example, with all else being equal, one
would be less likely to encounter small cell counts with
60% verified compared to 10% verified. To test whether
small cell counts or overall verification rates drove our
findings, we repeated our simulations using probabilities
of verification as shown in the bottom half of table 2: in
this case, the probability of small numbers of false nega-
tives is higher in the scenario with a higher overall verifi-
cation rate. For the simulations, the AUC was calculated
by estimating sensitivity and specificity over 10 categories
based on the deciles of the diagnostic test result; we did
not calculate the AUC using the Alonzo-Pepe method as it
gave similar results. All statistical analyses were conducted
using Stata 9.2 (StataCorp, College Station, TX).
Results
Simulation studies
Data simulated under the setting of a screening study with
5000 participants are shown in Table 3. Defining "false
negatives" as participants below the median diagnostic
test level with a positive gold standard result, 99/2500
(4.0%) were false negatives. Table 3 also shows five exam-
ple runs of our simulation. After verification bias was ran-
domly introduced the first time, only 50 (2% of 2500)
participants below the median diagnostic test level had
gold standard assessment of which 2 were false negatives.
We introduced verification bias to the same simulated
data set 4 more times. Comparing the replications, we
observe no important differences in the proportion of par-
ticipants below the median diagnostic test level who sub-
sequently underwent gold standard assessment (1.6% –
2.6%). We also observe that the proportions of false neg-
atives in each replication are consistent with chance when
compared to the 4.0% of false negatives in the fully veri-
fied data set. Notably, the number of false negatives
encountered ranged from 0–4. AUC corrected for verifica-
tion bias ranged from 0.550 to 0.852. The variation in
these results is very large: few estimates of AUC in the
medical literature are less than 0.55 or greater than 0.85.
In other words, two replications of a screening study could
produce results at opposite ends of the extremes of test
characteristics. The estimates of AUC using the Alonzo-
Pepe method showed similar gross variability, indicating
that the variation in results is not explained by categoriz-
ing the continuous diagnostic test result in 10 groups.
Similar results were observed when varying the true value
Table 3: Example of data generated under the setting of a screening study with 5000 participants and the underlying incidence of 
disease being 10%
(1) (2)
Data Set Number with negative 
diagnostic test and verified
Number of false negatives Proportion of false 
negatives (2)/(1)
AUC
Categorize in 10 bins Alonzo-Pepe
Fully verified 2500 99 4.0% 0.750 0.750
With verification bias
Replication 1 50 (2.0%) 2 4.0% 0.690 0.712
Replication 2 64 (2.6%) 4 6.3% 0.852 0.857
Replication 3 40 (1.6%) 2 5.0% 0.550 0.546
Replication 4 61 (2.4%) 0 0.0% 0.812 0.826
Replication 5 65 (2.6%) 3 4.6% 0.790 0.803
In the fully verified data set, definitive test results were known for all 5000 participants. In the replications with verification bias, only 500 (10%) 
participants underwent definitive testing. False negatives are defined as verified participants with a diagnostic test result less than the median of the 
diagnostic test results and with a positive gold standard result. The AUC of the fully verified data set was 0.750; all other estimates are with 
correction for verification bias.Page 5 of 9
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highly predictive tests (for example, AUC of 0.9, table 4).
The results of the simulation study are shown in table 5.
The number of false negatives is shown for a cut-off at the
2nd decile. With 10% of participants verified, 0 false nega-
tives were encountered in 83% of the replications; 1 false
negative in 16%, and > 1 false negative in 2%. The propor-
tion of replications with > 1 false negative increased as the
percentage verified increased. With 30% of participants
verified, 23% of replications had > 1 false negative; this
proportion rose to 92% with 60% of participants verified.
The verification bias corrected AUC had little bias: the
mean over 2000 replications was generally close to the
true AUC of 0.750. As expected, presence of verification
bias increased the amount of variability associated with
the AUC. With full verification, the 2.5th – 95th percentiles
of the AUC over 2000 replications were 0.728 – 0.774;
with 10% of participants verified, which is commonly
observed in screening settings, this increased to 0.577 –
0.860. The width of this interval, 0.28, covers approxi-
mately 60% of all possible values of AUC. One way of
illustrating these results is to note that a study with only
100 patients and a 10% event rate has a confidence inter-
val for AUC of approximately 0.3: thus a study with 5000
patients that is subject to verification bias has equivalent
statistical precision to one 98% smaller. Coverage was
only 77% when 10% of patients were verified. As
expected, both variability and coverage improved with a
higher proportion verified: with 60% of participants veri-
fied, the 2.5th – 95th percentiles of the AUC were 0.713 –
0.786 and coverage was 93%.
Table 5 gives the results for the scenarios in the bottom
half of table 2, where the number of false negatives is
higher when the overall verification rate is lower. It is clear
that the false negative count determines the value of veri-
fication bias correction: even if, overall, a reasonable
number of patients are verified (60%), our estimates have
poor properties when there are few false negatives.
Published example 1 – HPV, cervical cancer example
In 2004, Dannecker et al examined the sensitivity of
human papillomavirus (HPV) DNA on self-collected vag-
inal swabs for the diagnosis of cervical cancer [8]. The
study included 435 participants in total, of whom 122
(28%) underwent colposcopy, the gold standard assess-
ment. The paper reported a sensitivity of 100% after veri-
fication bias correction, yet it is clear from examination of
the paper that there were no false negatives. If instead
there was 1 false negative (e.g. 1 participant with a nega-
tive diagnostic test result who was positive on colpos-
copy), the sensitivity after verification bias correction
would be markedly reduced, from 100% to 70%. Since
there were zero false negatives, verification bias corrected
confidence intervals cannot be derived (the authors did
not provide confidence intervals, and did not mention the
variability associated with the estimated sensitivity).
Published example 2 – CAD, Single Photon Emission 
Computed Tomography
In 2002, Miller et al examined the sensitivity of single
photon emission computed tomography (SPECT) for the
diagnosis of coronary artery disease (CAD) [7]. The study
included 14,273 participants in total, of whom 1853
(13%) underwent coronary angiography, the gold stand-
ard assessment. This paper reported a sensitivity of 65%
(95% confidence interval 63 to 68%) after verification
bias correction. There were 32 false negatives in the study.
Small changes to the number of false negatives did not
have a substantive difference in this example. For exam-
ple, we estimate that changing the number of false nega-
tives to 25 would result in a corrected sensitivity of 68%,
and to 40 would result in a corrected sensitivity of 62%;
these estimates are not importantly different from the
reported sensitivity of 65%, and are nearly within the
reported 95% confidence interval. From reviewing the sta-
tistical methods of the manuscript, we hypothesize that
the reported confidence intervals are too narrow because
the analysis included stepwise model selection, which was
not replicated during the bootstrap procedure.
Published example 3 – PSA, prostate cancer example
In 2003, Punglia et al reported the AUC of a PSA test for
prostate cancer diagnosis in a screening study conducted
in the United States [4]. Of 6,691 men with PSA results,
705 (11%) underwent biopsy of the prostate. The investi-
gators performed a verification bias correction and
reported the AUC of the PSA test for men aged < 60 years
to be 0.86. From the presented tables and figures for men
aged < 60 years, we observe that the corrected sensitivity
remained at 100% for PSA < 0.9 ng/ml. This implies that
there were no false negatives among men aged < 60 years
with PSA < 0.9 ng/ml. Using simple assumptions (the
median PSA among all 4556 men < 60 screened being 0.9
ng/ml and holding the specificity at this PSA level around
Table 4: Examples of estimates of verification bias corrected 
AUC when varying the true value of the AUC
AUC
Fully verified (True value) 0.600 0.700 0.800 0.900
With verification bias correction
Replication 1 0.284 0.503 0.688 0.873
Replication 2 0.754 0.838 0.742 0.894
Replication 3 0.567 0.578 0.740 0.873
Replication 4 0.689 0.779 0.883 0.920
Replication 5 0.648 0.755 0.856 0.827Page 6 of 9
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negatives, from 0 to 1, the corrected sensitivity drops to
80%. Had the AUC been calculated using 80% sensitivity
instead of 100% sensitivity for PSA < 0.9 ng/ml, then the
corrected AUC would be 0.78 instead of 0.86. Confidence
intervals were not provided by the author for any sensitiv-
ity or AUC estimates.
Discussion
Verification bias is present in studies where only a subset
of subjects receives the gold standard confirmation of dis-
ease status and where the likelihood of the gold standard
confirmation depends on the diagnostic test result. These
two conditions are often met in screening studies. When
verification bias is not accounted for, reported sensitivity
is inflated and specificity is understated. It is possible to
obtain verification bias-corrected estimates of sensitivity
and specificity if at least 1 subject with a negative screen-
ing test receives the definitive testing.
Several systematic reviews have investigated the preva-
lence of verification bias in diagnostic studies. In a review
of pediatric studies published from 1987 to 1989, 40%
(15/42) were found to be verification bias[14]. Reviewing
all diagnostic test studies published from 1978 to 1993,
correction for verification bias was performed in 46% (51/
112) studies. Notably, the proportion of studies that cor-
rected for verification bias significantly increased over
time: 29% from 1978–1981 and 62% from 1990–1993.
Finally, in a review of studies examining diagnostic tests
for cancer published from 1990 to 2003, 40% (10/25) at
least mentioned verification bias as a potential source for
bias[15].
It is important to recognize not only the need for but also
the limitations of verification bias correction. In this
paper, we illustrate that standard methods for verification
bias correction are not adequate when there are few false
negatives. This situation is commonly encountered in
screening studies [4,8]. In these cases, verification bias
correction would have led to dramatically different results
given very small changes in the number of false negatives.
Most skilled statisticians would be wary about applying
statistical methods when there are low cell counts, and
would therefore be concerned about the adequacy of ver-
ification bias correction in this circumstance. Yet we have
shown that verification bias correction is often applied
regardless of low numbers of false negatives. In the HPV
example, the authors concluded that the HPV DNA test
had excellent sensitivity, when in fact the reported sensi-
tivity of 100% would have been 70% were a single patient
to be reclassified. In the PSA screening example, the AUC
could have been 0.78 instead of 0.86 if a single cancer
were found among the estimated 2300 men with PSA <
0.9 ng/ml. Although PSA is a screening test with a contin-
uous distribution, it should be noted that verification
bias-corrected estimates should not be obtained for PSA
levels below which no man receives a biopsy. Indeed,
using data from the Prostate Cancer Prevention Trial[16],
a study in which men were biopsied irrespective of PSA
level and thus not subject to verification bias, we might
estimate well over 100 false negatives in the PSA < 0.9 ng/
ml group.
One possible solution to low false negative rates would be
to provide confidence intervals, so that the width of the
confidence interval can give insight into the certainty of
the point estimate. Begg and Greenes provide formulas to
calculate confidence intervals in the presence of verifica-
tion bias, however, these formulas are based on asymp-
totic theory. In the case of few false negatives, the resulting
confidence intervals will be insufficiently wide due to the
Table 5: Simulation study with 2000 replications
Percentage Verified Proportion with n false negatives AUC over 2000 replications Coverage Probability over 2000 replications
n = 0 n = 1 n = 2 n > 2 Mean 2.5th – 97.5th percentile
Probabilities of verification likely to be encountered in a screening study
True n/a n/a n/a n/a 0.750 0.728, 0.774 95%
10% 83% 16% 2% 0% 0.758 0.577, 0.860 77%
30% 41% 37% 17% 6% 0.752 0.677, 0.813 89%
60% 1% 6% 12% 80% 0.750 0.713, 0.786 93%
Probabilities of verification were adjusted such that false negatives were more (less) likely to be present for 10% (60%) verified
10% 25% 35% 23% 16% 0.751 0.677, 0.820 93%
60% 98% 3% 0% 0% 0.728 0.552, 0.819 67%
5000 participants are enrolled in a screening study with an underlying incidence of disease of 10%. False negatives are defined as verified participants 
with a diagnostic test result less than the 20th percentile of the diagnostic test results and with a positive gold standard result.Page 7 of 9
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ous distribution-free method to calculate confidence
intervals is by bootstrapping. However, since the false
negative rate is underestimated in data subject to verifica-
tion bias, we cannot be certain that resampling methods
will sample from the true distribution of false negatives,
in particular when the diagnostic test has a continuous
distribution. For example, consider the case where the
diagnostic test is continuous and there is only one false
negative with a test result t = t* below a threshold value of
the test q. Resampling methods will give a value t = t* for
all diseased subjects below q, which is not the true distri-
bution. As a result, bootstrap methods will provide overly
narrow confidence intervals (table 5). In the HPV exam-
ple, since the actual data did not contain any false nega-
tives, no bootstrap sample would contain any false
negatives; hence, the sensitivity would be overestimated
in all bootstrap samples. Therefore, we do not believe that
bootstrap methods to produce verification bias corrected
confidence intervals are appropriate.
We have described the application of certain statistical
methods in the presence of verification bias, and the prob-
lems with these methods when the analysis data set con-
tains few false negatives. In other words, this manuscript
focuses on the analytic phase of the study, and not the
design phase. If it is known in advance that verification
bias will be an issue, then a possible solution would be to
design the study such that a random sample of test-nega-
tive subjects to undergo disease verification. The size of
this sample would need to be sufficiently large to provide
an adequate number of false negatives to estimate sensi-
tivity, which may be difficult to determine in the original
study design. In the CAD example, less than 2% of the test
negative participants (97/6745) were in the verified sam-
ple; a higher percentage of test negatives in the verified
sample would be required in a smaller study. Although
verification bias corrected estimates of diagnostic accuracy
would be improved, this would come at a cost: subjects
with no indication of disease would undergo unnecessary
procedures, possibly resulting in complications and dis-
comfort, not to mention the monetary cost of the addi-
tional procedures. The appropriateness of randomly
selecting test-negative subjects to receive the gold standard
assessment will be specific to the disease (for example, the
incidence of disease and the invasiveness of the gold
standard assessment. Since the focus of this manuscript is
data analysis, and not study design, we have not made
specific recommendations on this point.
For our simulations, we used data sets with 5000 subjects,
a 10% incidence of disease and a verification rate as low
as 10%. These numbers were chosen to reflect the typical
parameters of screening studies. For example, in one cer-
vical cancer study, 364 of 4761 (8%) women underwent
biopsy [9]; the biopsy rate was 705 of 6691 (11%) of men
in a prostate cancer screening study; in a cardiovascular
study 340/3679 (9%) patients underwent angiography for
disease status confirmation [5]. With respect to the true
incidence of disease, this is naturally difficult to deter-
mine. As such, we conservatively chose a high incidence of
10% (note that, for example, the lifetime incidence of cer-
vical cancer is less than 1%[17]). It thus seems plausible
that many screening studies would be prey to the problem
of low false negative rates. The published examples (3.2 –
3.4 above) provide additional evidence on this point.
Previous mention has been made to the inadequacy of
verification bias correction in the presence of low false
negatives. In their critique of a novel imputation method,
Hanley et al noted that sensitivity was 100% when there
were no false negatives, even after verification bias correc-
tion. They cautioned against verification bias correction
when one or more of the cells in the verified sample is
zero [18]. Pepe has previously noted that verification bias
corrected estimates of sensitivity are not robust to low
numbers of false negatives[13]. We further demonstrate
that standard methods to correct for verification bias,
which have been widely used with zero false negatives,
will produce unreliable estimates of sensitivity and AUC.
Ultimately, verification bias is a missing data problem
and we hypothesize that no correction method will be
able to overcome a cell count of zero.
Conclusion
The characteristics of diagnostic tests have important clin-
ical implications. From these results, clinicians decide
whether or not to use a diagnostic test, and if so, how it
should be used, such as what PSA cutoff to use to recom-
mend patients for biopsy. Screening programs are
designed such that few false negatives are encountered.
When there are few false negatives, standard methods for
verification bias correction are inadequate. If these meth-
ods are to be used, then at a minimum verification bias
corrected confidence intervals should be provided for all
estimates of diagnostic accuracy. Investigators should be
cautioned when using such methods: there are no "free
lunches" in statistics, and we should certainly be skeptical
of methods that appear to get something from nothing.
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